# Autonomix Medical, Inc.: overview

AMIX · Nasdaq · CIK 1617867 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/amix.md) · [Financials](/companies/amix/financials.md) · [Filings](/companies/amix/filings.md) · [Insiders](/companies/amix/insiders.md)

Latest reported revenue: [$0](/filings/0001437749-26-027429.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001437749-26-027429).

## Last eight quarters

| Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0001437749-25-034517.md) | [0.0](/filings/0001437749-26-003816.md) | [0.0 d](/filings/0001437749-26-018573.md) | [0.0](/filings/0001437749-26-027429.md) | [0.0](/filings/0001437749-25-034517.md) | [0.0](/filings/0001437749-26-003816.md) | [0.0 d](/filings/0001437749-26-018573.md) | [0.0](/filings/0001437749-26-027429.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $k | [(1,596) d](/filings/0001437749-25-034517.md) | [(2,306) d](/filings/0001437749-26-003816.md) | [(8,272)](/filings/0001437749-25-018831.md) | [(2,604)](/filings/0001437749-26-027429.md) | [(3,817) d](/filings/0001437749-25-034517.md) | [(2,976) d](/filings/0001437749-26-003816.md) | [(2,895) d](/filings/0001437749-26-018573.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001437749-24-018932.md) | [0.0](/filings/0001437749-25-018831.md) | [0.0](/filings/0001437749-26-018573.md) | [0.0](/filings/0001437749-26-018573.md) |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [(1.9)](/filings/0001437749-24-018932.md) | [(6.6)](/filings/0001437749-25-018831.md) | [(8.3)](/filings/0001437749-26-018573.md) | [(12.3)](/filings/0001437749-26-018573.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/amix/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Mariner, LLC](/funds/1373442.md) | 2026-06-30 | $25.6k | 50,138 |  | New +50,138 |
| [Allied Private Wealth LLC](/funds/2132253.md) | 2026-06-30 | $2.2k | 347 |  | Not compared |
| [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $1.9k | 313 |  | New +313 |
| [PNC Financial Services Group, Inc.](/funds/713676.md) | 2026-06-30 | $467 | 75 |  | New +75 |
| [Investors Research Corp](/funds/1730630.md) | 2026-06-30 | $50 | 8 |  | New +8 |
| [Networth Advisors, LLC](/funds/2099019.md) | 2026-06-30 | $6 | 1 |  | New +1 |

## Recent filings

[All 148 filings](/companies/amix/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-16 | 12:35 ET | [8-K](/filings/0001437749-26-030505.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-26-030505 |
| 2026-09-14 | 21:02 ET | [DEF 14A](/filings/0001437749-26-030345.md) | Proxy statement, period 2026-10-29 | 0001437749-26-030345 |
| 2026-08-26 | 21:02 ET | [8-K](/filings/0001437749-26-029024.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-029024 |
| 2026-08-13 | 23:40 ET | [10-Q](/filings/0001437749-26-027429.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027429 |
| 2026-07-28 | 15:36 ET | [8-K](/filings/0001437749-26-024597.md) | 8.01 Other events | 0001437749-26-024597 |
| 2026-07-15 | 21:02 ET | [8-K](/filings/0001437749-26-023638.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-023638 |
| 2026-07-10 | 12:32 ET | [8-K](/filings/0001437749-26-023248.md) | 8.01 Other events | 0001437749-26-023248 |
| 2026-06-24 | 11:00 ET | [8-K](/filings/0001437749-26-021495.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-021495 |
| 2026-06-15 | 21:28 ET | [10-K/A](/filings/0001437749-26-020686.md) | Annual report, amended, period 2026-03-31 | 0001437749-26-020686 |
| 2026-05-27 | 20:30 ET | [10-K](/filings/0001437749-26-018573.md) | Annual report, period 2026-03-31 | 0001437749-26-018573 |

## Latest annual report

[Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001437749-26-018573.md), filed May 27, 2026.

## Forecast league

Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/863873d8-5e83-4791-9cc5-d561f0a3f99d)

## About the filer

- CIK: 1617867
- Tickers: AMIX
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.